The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant chemoradiotherapy (CRT) plus pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC) with high risk of recurrence after neoadjuvant CRT plus surgery: A single-arm phase II study.
 
Jhe-Cyuan Guo
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Merck Serono; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Merck Serono; Ono Pharmaceutical
Travel, Accommodations, Expenses - Ipsen; Novartis; Ono Pharmaceutical
 
Ta-Chen Huang
No Relationships to Disclose
 
Hung-Yang Kuo
No Relationships to Disclose
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche
Consulting or Advisory Role - Abbvie; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; IMPAC Medical Systems; Novartis; PharmaEngine
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; IMPAC Medical Systems; Lilly
 
Feng-Ming Hsu
Speakers' Bureau - AstraZeneca
Research Funding - Vysioneer
Travel, Accommodations, Expenses - AstraZeneca
 
Jason C. Cheng
No Relationships to Disclose
 
Yen-Lin Huang
No Relationships to Disclose
 
Min-Shu Hsieh
No Relationships to Disclose
 
Pei-Ming Huang
No Relationships to Disclose
 
Jang-Ming Lee
No Relationships to Disclose
 
Shu-Ling Wu
No Relationships to Disclose
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; MSD; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Eucure Biopharma (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); NGM Biopharmaceuticals (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo